News Celon Pharma S.A.

Equities

CLN

PLCLNPH00015

Market Closed - Warsaw S.E. Other stock markets 09:25:43 10/05/2024 pm IST			5-day change	1st Jan Change
16.12 ^PLN	0.00%		+3.87%	+4.27%

24/04	Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	25/04	CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	22/11	CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	20/23/20	CI
Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	24/23/24	CI
Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	23/22/23	CI
Celon Pharma S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	29/22/29	CI
Celon Pharma S.A. Reports Earnings Results for the First Quarter Ended March 31, 2022	25/22/25	CI
Celon Pharma S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	02/22/02	CI
Celon Pharma S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	29/21/29	CI
The results of CPL’36 – PDE10a inhibitor to be presented in the poster session at Neuroscience 2021.	02/21/02	PU
Celon Pharma S.A. at the Jefferies Healthcare Conference 2021.	26/21/26	PU
Celon Pharma S.A. Reports Earnings Results for the Second Quarter Ended June 30, 2021	30/21/30	CI
Celon Pharma S A : Doubled export sales, continuation of the strategy of investing in research and development	30/21/30	PU
Celon Pharma S A : 3 posters to be published at 34th ECNP Congress	14/21/14	PU
Celon Pharma Successfully Completes the First Stage of Clinical Research into its CPL'116 Drug Candidate for Treating Autoimmune Diseases	10/21/10	CI
Celon Pharma to Raise PLN 216mn in Public Offering	12/21/12	CI
Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes	22/21/22	CI
Celon Pharma S A : at EASD 2021	15/21/15	PU
Celon Pharma S A : Dynamic export and continuation of positive trends in the development of innovative products	26/21/26	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Celon Pharma S.A.

Equities

CLN

PLCLNPH00015

Summary

Filters